The Precision Peptide Genetic Test identifies your unique variants in GLP1R, GIPR, FTO, and MC4R pathways, revealing how your genetics influence semaglutide response across 49 peptides and 14 biological pathways
Slowing or Preventing Disease Progression For patients with MASLD and type 2 diabetes, early use of GLP-1 medications may help prevent progression to more advanced stages of liver disease, including fibrosis and cirrhosis
The development of a manifold single pharmacological agent like tirzepatide that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia at an early clinical stage is enormously important
The primary endpoint was resolution of NASH with no liver fibrosis worsening in people with initial stage 2 or 3 fibrosis
Tesofensine is not FDA-approved for any indication.
Kefir: a fermented plethora of symbiotic microbiome and health